Immunologically mediated liver diseases belong to the common extraintestinal manifestations of celiac disease. We have reviewed the current literature that addresses the association between celiac disease and liver disorders. We searched relevant articles on MEDLINE/PubMed up to 15 June 2018. The objective of the article is to provide a comprehensive and up-to-date review on the latest hypotheses explaining the pathogenetic relationship between celiac disease and liver injury. Besides the involvement of gut⁻liver axis, tissue transglutaminase antibodies, and impairment of intestinal barrier, we integrate the latest achievements made in elucidation of the role of gut microbiota in celiac disease and liver disorders, that has not yet been sufficiently discussed in the literature in this context. The further objective is to provide a complete clinical overview on the types of liver diseases frequently found in celiac disease. In conclusion, the review highlights the clinical implication, recommend a rational approach for managing elevated transaminases in celiac patients, and underscore the importance of screening for celiac disease in patients with associated liver disease.

2nd Department of Internal Medicine 3rd Faculty of Medicine Charles University Ruska 87 100 00 Prague Czech Republic

Centre for Research on Nutrition Metabolism and Diabetes 3rd Faculty of Medicine Charles University Ruska 87 100 00 Prague Czech Republic

Laboratory of Cellular and Molecular Immunology Institute of Microbiology of the Czech Academy of Sciences v v i Videnska 1083 142 20 Prague Czech Republic

Zobrazit více v PubMed

Hagander B., Berg N.O., Brandt L., Norden A., Sjolund K., Stenstam M. Hepatic injury in adult coeliac disease. Lancet. 1977;2:270–272. doi: 10.1016/S0140-6736(77)90954-0. PubMed DOI

Vajro P., Paolella G., Maggiore G., Giordano G. Pediatric celiac disease, cryptogenic hypertransaminasemia, and autoimmune hepatitis. J. Pediatr. Gastroenterol. Nutr. 2013;56:663–670. doi: 10.1097/MPG.0b013e31828dc5c5. PubMed DOI

Sainsbury A., Sanders D.S., Ford A.C. Meta-analysis: Coeliac disease and hypertransaminasaemia. Aliment. Pharmacol. Ther. 2011;34:33–40. doi: 10.1111/j.1365-2036.2011.04685.x. PubMed DOI

Zanini B., Basche R., Ferraresi A., Pigozzi M.G., Ricci C., Lanzarotto F., Villanacci V., Lanzini A. Factors that contribute to hypertransaminasemia in patients with celiac disease or functional gastrointestinal syndromes. Clin. Gastroenterol. Hepatol. 2014;12:804–810. doi: 10.1016/j.cgh.2013.10.033. PubMed DOI

Lee G.J., Boyle B., Ediger T., Hill I. Hypertransaminasemia in Newly Diagnosed Pediatric Patients with Celiac Disease. J. Pediatr. Gastroenterol. Nutr. 2016;63:340–343. doi: 10.1097/MPG.0000000000001153. PubMed DOI

Aarela L., Nurminen S., Kivela L., Huhtala H., Maki M., Viitasalo A., Kaukinen K., Lakka T., Kurppa K. Prevalence and associated factors of abnormal liver values in children with celiac disease. Dig. Liver Dis. 2016;48:1023–1029. doi: 10.1016/j.dld.2016.05.022. PubMed DOI

Mirzaagha F., Azali S.H., Islami F., Zamani F., Khalilipour E., Khatibian M., Malekzadeh R. Coeliac disease in autoimmune liver disease: A cross-sectional study and a systematic review. Dig. Liver Dis. 2010;42:620–623. doi: 10.1016/j.dld.2010.02.006. PubMed DOI

Volta U., Caio G., Tovoli F., De Giorgio R. Gut-liver axis: An immune link between celiac disease and primary biliary cirrhosis. Expert Rev. Gastroenterol. Hepatol. 2013;7:253–261. doi: 10.1586/egh.13.5. PubMed DOI

Robinson M.W., Harmon C., O’Farrelly C. Liver immunology and its role in inflammation and homeostasis. Cell. Mol. Immunol. 2016;13:267–276. doi: 10.1038/cmi.2016.3. PubMed DOI PMC

Carambia A., Herkel J. Dietary and metabolic modulators of hepatic immunity. Semin. Immunopathol. 2018;40:175–188. doi: 10.1007/s00281-017-0659-4. PubMed DOI

Husby S. Normal immune responses to ingested foods. J. Pediatr. Gastroenterol. Nutr. 2000;30:S13–S19. doi: 10.1097/00005176-200001001-00003. PubMed DOI

Wiest R., Albillos A., Trauner M., Bajaj J.S., Jalan R. Targeting the gut–liver axis in liver disease. J. Hepatol. 2017;67:1084–1103. doi: 10.1016/j.jhep.2017.05.007. PubMed DOI

Sturgeon C., Fasano A. Zonulin, a regulator of epithelial and endothelial barrier functions, and its involvement in chronic inflammatory diseases. Tissue Barriers. 2016;4:e1251384. doi: 10.1080/21688370.2016.1251384. PubMed DOI PMC

Schneider K.M., Albers S., Trautwein C. Role of bile acids in the gut–liver axis. J. hepatol. 2018;68:1083–1085. doi: 10.1016/j.jhep.2017.11.025. PubMed DOI

Pekarikova A., Sanchez D., Palova-Jelinkova L., Simsova M., Benes Z., Hoffmanova I., Drastich P., Janatkova I., Mothes T., Tlaskalova-Hogenova H., et al. Calreticulin is a B cell molecular target in some gastrointestinal malignancies. Clin. Exp. Immunol. 2010;160:215–222. doi: 10.1111/j.1365-2249.2009.04085.x. PubMed DOI PMC

Sanchez D., Tuckova L., Mothes T., Kreisel W., Benes Z., Tlaskalova-Hogenova H. Epitopes of calreticulin recognised by IgA autoantibodies from patients with hepatic and coeliac disease. J. Autoimmun. 2003;21:383–392. doi: 10.1016/S0896-8411(03)00137-9. PubMed DOI

Lerner A., Aminov R., Matthias T. Transglutaminases in Dysbiosis As Potential Environmental Drivers of Autoimmunity. Front. Microbiol. 2017;8:66. doi: 10.3389/fmicb.2017.00066. PubMed DOI PMC

Federico A., Dallio M., Caprio G.G., Ormando V.M., Loguercio C. Gut microbiota and the liver. Minerva Gastroenterol. Dietol. 2017;63:385–398. PubMed

De Re V., Magris R., Cannizzaro R. New Insights into the Pathogenesis of Celiac Disease. Front. Med. 2017;4:137. doi: 10.3389/fmed.2017.00137. PubMed DOI PMC

Spadoni I., Zagato E., Bertocchi A., Paolinelli R., Hot E., Di Sabatino A., Caprioli F., Bottiglieri L., Oldani A., Viale G., et al. A gut–vascular barrier controls the systemic dissemination of bacteria. Science. 2015;350:830–834. doi: 10.1126/science.aad0135. PubMed DOI

Hoffmanova I., Sanchez D., Habova V., Andel M., Tuckova L., Tlaskalova-Hogenova H. Serological markers of enterocyte damage and apoptosis in patients with celiac disease, autoimmune diabetes mellitus and diabetes mellitus type 2. Physiol. Res. 2015;64:537–546. PubMed

Novacek G., Miehsler W., Wrba F., Ferenci P., Penner E., Vogelsang H. Prevalence and clinical importance of hypertransaminasaemia in coeliac disease. Eur. J. Gastroenterol. Hepatol. 1999;11:283–288. doi: 10.1097/00042737-199903000-00012. PubMed DOI

Fasano A. Zonulin, regulation of tight junctions, and autoimmune diseases. Ann. N. Y. Acad. Sci. 2012;1258:25–33. doi: 10.1111/j.1749-6632.2012.06538.x. PubMed DOI PMC

Saiman Y., Friedman S.L. The role of chemokines in acute liver injury. Front. Physiol. 2012;3:213. doi: 10.3389/fphys.2012.00213. PubMed DOI PMC

Chen W.L.K., Edington C., Suter E., Yu J., Velazquez J.J., Velazquez J.G., Shockley M., Large E.M., Venkataramanan R., Hughes D.J., et al. Integrated gut/liver microphysiological systems elucidates inflammatory inter-tissue crosstalk. Biotechnol. Bioeng. 2017;114:2648–2659. doi: 10.1002/bit.26370. PubMed DOI PMC

Barilli A., Rotoli B.M., Visigalli R., Ingoglia F., Cirlini M., Prandi B., Dall’Asta V. Gliadin-mediated production of polyamines by RAW264.7 macrophages modulates intestinal epithelial permeability in vitro. Biochim. Biophys. Acta. 2015;1852:1779–1786. doi: 10.1016/j.bbadis.2015.06.001. PubMed DOI

Cinova J., Palova-Jelinkova L., Smythies L.E., Cerna M., Pecharova B., Dvorak M., Fruhauf P., Tlaskalova-Hogenova H., Smith P.D., Tuckova L. Gliadin peptides activate blood monocytes from patients with celiac disease. J. Clin. Immunol. 2007;27:201–209. doi: 10.1007/s10875-006-9061-z. PubMed DOI

Barilli A., Gaiani F., Prandi B., Cirlini M., Ingoglia F., Visigalli R., Rotoli B.M., de’Angelis N., Sforza S., de’Angelis G.L., et al. Gluten peptides drive healthy and celiac monocytes toward an M2-like polarization. J. Nutr. Bioch. 2018;54:11–17. doi: 10.1016/j.jnutbio.2017.10.017. PubMed DOI

Verdu E.F., Galipeau H.J., Jabri B. Novel players in coeliac disease pathogenesis: Role of the gut microbiota. Nat. Rev. Gastroenterol. Hepatol. 2015;12:497–506. doi: 10.1038/nrgastro.2015.90. PubMed DOI PMC

Cenit M.C., Olivares M., Codoner-Franch P., Sanz Y. Intestinal Microbiota and Celiac Disease: Cause, Consequence or Co-Evolution? Nutrients. 2015;7:6900–6923. doi: 10.3390/nu7085314. PubMed DOI PMC

Woodhouse C.A., Patel V.C., Singanayagam A., Shawcross D.L. Review article: The gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease. Aliment. Pharmacol. Ther. 2018;47:192–202. doi: 10.1111/apt.14397. PubMed DOI

Sabino J., Vieira-Silva S., Machiels K., Joossens M., Falony G., Ballet V., Ferrante M., van Assche G., Van der Merwe S., Vermeire S., et al. Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD. Gut. 2016;65:1681–1689. doi: 10.1136/gutjnl-2015-311004. PubMed DOI PMC

Grander C., Adolph T.E., Wieser V., Lowe P., Wrzosek L., Gyongyosi B., Ward D.V., Grabherr F., Gerner R.R., Pfister A., et al. Recovery of ethanol-induced Akkermansia muciniphila depletion ameliorates alcoholic liver disease. Gut. 2018;67:891–901. doi: 10.1136/gutjnl-2016-313432. PubMed DOI

Szebeni B., Veres G., Dezsofi A., Rusai K., Vannay A., Bokodi G., Vasarhelyi B., Korponay-Szabo I.R., Tulassay T., Arato A. Increased mucosal expression of Toll-like receptor (TLR)2 and TLR4 in coeliac disease. J. Pediatr. Gastroenterol. Nutr. 2007;45:187–193. doi: 10.1097/MPG.0b013e318064514a. PubMed DOI

Cenit M.C., Codoner-Franch P., Sanz Y. Gut Microbiota and Risk of Developing Celiac Disease. J. Clin. Gastroenterol. 2016;50(Suppl. 2):S148–S152. doi: 10.1097/MCG.0000000000000688. PubMed DOI

Fukui H. Gut Microbiota and Host Reaction in Liver Diseases. Microorganisms. 2015;3:759–791. doi: 10.3390/microorganisms3040759. PubMed DOI PMC

Del Campo J.A., Gallego P., Grande L. Role of inflammatory response in liver diseases: Therapeutic strategies. World J. Hepatol. 2018;10:1–7. doi: 10.4254/wjh.v10.i1.1. PubMed DOI PMC

Schnabl B., Brenner D.A. Interactions between the intestinal microbiome and liver diseases. Gastroenterology. 2014;146:1513–1524. doi: 10.1053/j.gastro.2014.01.020. PubMed DOI PMC

Hartmann P., Hochrath K., Horvath A., Chen P., Seebauer C.T., Llorente C., Wang L., Alnouti Y., Fouts D.E., Starkel P., et al. Modulation of the intestinal bile acid/farnesoid X receptor/fibroblast growth factor 15 axis improves alcoholic liver disease in mice. Hepatology. 2018;67:2150–2166. doi: 10.1002/hep.29676. PubMed DOI PMC

Deutschmann K., Reich M., Klindt C., Droge C., Spomer L., Haussinger D., Keitel V. Bile acid receptors in the biliary tree: TGR5 in physiology and disease. Biochim. Biophys. Acta. 2018;1864:1319–1325. doi: 10.1016/j.bbadis.2017.08.021. PubMed DOI

Pelaez-Luna M., Schmulson M., Robles-Diaz G. Intestinal involvement is not sufficient to explain hypertransaminasemia in celiac disease? Med. Hypotheses. 2005;65:937–941. doi: 10.1016/j.mehy.2005.05.013. PubMed DOI

Griffin M., Casadio R., Bergamini C.M. Transglutaminases: Nature’s biological glues. Biochim. J. 2002;368:377–396. doi: 10.1042/bj20021234. PubMed DOI PMC

Elli L., Bergamini C.M., Bardella M.T., Schuppan D. Transglutaminases in inflammation and fibrosis of the gastrointestinal tract and the liver. Dig. Liver Dis. 2009;41:541–550. doi: 10.1016/j.dld.2008.12.095. PubMed DOI

Drastich P., Honsova E., Lodererova A., Jaresova M., Pekarikova A., Hoffmanova I., Tuckova L., Tlaskalova-Hogenova H., Spicak J., Sanchez D. Celiac disease markers in patients with liver diseases: A single center large scale screening study. World J. Gastroenterol. 2012;18:6255–6262. doi: 10.3748/wjg.v18.i43.6255. PubMed DOI PMC

Esposito C., Paparo F., Caputo I., Rossi M., Maglio M., Sblattero D., Not T., Porta R., Auricchio S., Marzari R., et al. Anti-tissue transglutaminase antibodies from coeliac patients inhibit transglutaminase activity both in vitro and in situ. Gut. 2002;51:177–181. doi: 10.1136/gut.51.2.177. PubMed DOI PMC

Korponay-Szabo I.R., Halttunen T., Szalai Z., Laurila K., Kiraly R., Kovacs J.B., Fesus L., Maki M. In vivo targeting of intestinal and extraintestinal transglutaminase 2 by coeliac autoantibodies. Gut. 2004;53:641–648. doi: 10.1136/gut.2003.024836. PubMed DOI PMC

Sanchez D., Tuckova L., Sebo P., Michalak M., Whelan A., Sterzl I., Jelinkova L., Havrdova E., Imramovska M., Benes Z., et al. Occurrence of IgA and IgG autoantibodies to calreticulin in coeliac disease and various autoimmune diseases. J. Autoimmun. 2000;15:441–449. doi: 10.1006/jaut.2000.0452. PubMed DOI

Hoffmanova I., Sanchez D., Dzupa V. Bone and Joint Involvement in Celiac Disease. Acta Chir. Orthop. Traumatol. Cech. 2015;82:308–312. PubMed

Rubio-Tapia A., Murray J.A. Liver involvement in celiac disease. Minerva Med. 2008;99:595–604. PubMed PMC

Narciso-Schiavon J.L., Schiavon L.L. To screen or not to screen? Celiac antibodies in liver diseases. World J. Gastroenterol. 2017;23:776–791. doi: 10.3748/wjg.v23.i5.776. PubMed DOI PMC

Freeman H.J. Hepatic manifestations of celiac disease. Clin. Exp. Gastroenterol. 2010;3:33–39. doi: 10.2147/CEG.S7556. PubMed DOI PMC

Ludvigsson J.F., Elfstrom P., Broome U., Ekbom A., Montgomery S.M. Celiac disease and risk of liver disease: A general population-based study. Clin. Gastroenterol. Hepatol. 2007;5:63–69. doi: 10.1016/j.cgh.2006.09.034. PubMed DOI

Peters U., Askling J., Gridley G., Ekbom A., Linet M. Causes of death in patients with celiac disease in a population-based Swedish cohort. Arch. Intern. Med. 2003;163:1566–1572. doi: 10.1001/archinte.163.13.1566. PubMed DOI

Vancikova Z., Chlumecky V., Sokol D., Horakova D., Hamsikova E., Fucikova T., Janatkova I., Ulcova-Gallova Z., Stepan J., Limanova Z., et al. The serologic screening for celiac disease in the general population (blood donors) and in some high-risk groups of adults (patients with autoimmune diseases, osteoporosis and infertility) in the Czech Republic. Folia Microbiol. 2002;47:753–758. doi: 10.1007/BF02818684. PubMed DOI

Maggiore G., Caprai S. The liver in celiac disease. J. Pediatr. Gastroenterol. Nutr. 2003;37:117–119. doi: 10.1097/00005176-200308000-00006. PubMed DOI

Volta U., De Franceschi L., Lari F., Molinaro N., Zoli M., Bianchi F.B. Coeliac disease hidden by cryptogenic hypertransaminasaemia. Lancet. 1998;352:26–29. doi: 10.1016/S0140-6736(97)11222-3. PubMed DOI

Bardella M.T., Fraquelli M., Quatrini M., Molteni N., Bianchi P., Conte D. Prevalence of hypertransaminasemia in adult celiac patients and effect of gluten-free diet. Hepatology. 1995;22:833–836. PubMed

Kaukinen K., Halme L., Collin P., Farkkila M., Maki M., Vehmanen P., Partanen J., Hockerstedt K. Celiac disease in patients with severe liver disease: Gluten-free diet may reverse hepatic failure. Gastroenterology. 2002;122:881–888. doi: 10.1053/gast.2002.32416. PubMed DOI

Rubio-Tapia A., Murray J.A. The liver in celiac disease. Hepatology. 2007;46:1650–1658. doi: 10.1002/hep.21949. PubMed DOI

Stevens F.M., McLoughlin R.M. Is coeliac disease a potentially treatable cause of liver failure? Eur. J. Gastroenterol. Hepatol. 2005;17:1015–1017. doi: 10.1097/00042737-200510000-00002. PubMed DOI

Ecevit C., Karakoyun M., Unal F., Yuksekkaya H.A., Doganavsargil B., Yagci R.V., Aydogdu S. An autoimmune disease refractory to immunosuppressive regimens: Celiac disease diagnosed long after liver transplantation. Pediatr. Transpl. 2013;17:E156–E160. doi: 10.1111/petr.12136. PubMed DOI

Casswall T.H., Papadogiannakis N., Ghazi S., Nemeth A. Severe liver damage associated with celiac disease: Findings in six toddler-aged girls. Eur. J. Gastroenterol. Hepatol. 2009;21:452–459. doi: 10.1097/MEG.0b013e32830e1f12. PubMed DOI

Majumdar K., Sakhuja P., Puri A.S., Gaur K., Haider A., Gondal R. Coeliac disease and the liver: spectrum of liver histology, serology and treatment response at a tertiary referral centre. J. Clin. Pathol. 2018;71:412–419. doi: 10.1136/jclinpath-2017-204647. PubMed DOI

Rubio-Tapia A., Rahim M.W., See J.A., Lahr B.D., Wu T.-T., Murray J.A. Mucosal recovery and mortality in adults with celiac disease after treatment with a gluten-free diet. Am. J. Gastroenterol. 2010;105:1412–1420. doi: 10.1038/ajg.2010.10. PubMed DOI PMC

Newnham E.D., Shepherd S.J., Strauss B.J., Hosking P., Gibson P.R. Adherence to the gluten-free diet can achieve the therapeutic goals in almost all patients with coeliac disease: A 5-year longitudinal study from diagnosis. J. Gastroenterol. Hepatol. 2016;31:342–349. doi: 10.1111/jgh.13060. PubMed DOI

Dickey W., McMillan S.A., Collins J.S., Watson R.G., McLoughlin J.C., Love A.H. Liver abnormalities associated with celiac sprue. How common are they, what is their significance, and what do we do about them? J. Clin. Gastroenterol. 1995;20:290–292. doi: 10.1097/00004836-199506000-00006. PubMed DOI

Korpimaki S., Kaukinen K., Collin P., Haapala A.-M., Holm P., Laurila K., Kurppa K., Saavalainen P., Haimila K., Partanen J., et al. Gluten-sensitive hypertransaminasemia in celiac disease: An infrequent and often subclinical finding. Am. J. Gastroenterol. 2011;106:1689–1696. doi: 10.1038/ajg.2011.134. PubMed DOI

Rubio-Tapia A., Murray J.A. Celiac disease beyond the gut. Clin. Gastroenterol. Hepatol. 2008;6:722–723. doi: 10.1016/j.cgh.2008.03.017. PubMed DOI PMC

Marciano F., Savoia M., Vajro P. Celiac disease-related hepatic injury: Insights into associated conditions and underlying pathomechanisms. Dig. Liver Dis. 2016;48:112–119. doi: 10.1016/j.dld.2015.11.013. PubMed DOI

Nastasio S., Sciveres M., Riva S., Filippeschi I.P., Vajro P., Maggiore G. Celiac disease-associated autoimmune hepatitis in childhood: Long-term response to treatment. J. Pediatr. Gastroenterol. Nutr. 2013;56:671–674. doi: 10.1097/MPG.0b013e31828b1dfa. PubMed DOI

Di Biase A.R., Colecchia A., Scaioli E., Berri R., Viola L., Vestito A., Balli F., Festi D. Autoimmune liver diseases in a paediatric population with coeliac disease—A 10-year single-centre experience. Aliment. Pharmacol. Ther. 2010;31:253–260. PubMed

Caprai S., Vajro P., Ventura A., Sciveres M., Maggiore G. Autoimmune liver disease associated with celiac disease in childhood: A multicenter study. Clin. Gastroenterol. Hepatol. 2008;6:803–806. doi: 10.1016/j.cgh.2007.12.002. PubMed DOI

Ricano-Ponce I., Wijmenga C., Gutierrez-Achury J. Genetics of celiac disease. Best Pract. Res. Clin. Gastroenterol. 2015;29:399–412. doi: 10.1016/j.bpg.2015.04.004. PubMed DOI

Williamson K.D., Chapman R.W. Primary sclerosing cholangitis: A clinical update. Br. Med. Bull. 2015;114:53–64. doi: 10.1093/bmb/ldv019. PubMed DOI

Catassi C., Alaedini A., Bojarski C., Bonaz B., Bouma G., Carroccio A., Castillejo G., de Magistris L., Dieterich W., Di Liberto D., et al. The Overlapping Area of Non-Celiac Gluten Sensitivity (NCGS) and Wheat-Sensitive Irritable Bowel Syndrome (IBS): An Update. Nutrients. 2017;9:1268. doi: 10.3390/nu9111268. PubMed DOI PMC

Araujo A.R., Rosso N., Bedogni G., Tiribelli C., Bellentani S. Global epidemiology of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: What we need in the future. Liver Int. 2018;38(Suppl. 1):47–51. doi: 10.1111/liv.13643. PubMed DOI

Reilly N.R., Lebwohl B., Hultcrantz R., Green P.H.R., Ludvigsson J.F. Increased risk of non-alcoholic fatty liver disease after diagnosis of celiac disease. J. Hepatol. 2015;62:1405–1411. doi: 10.1016/j.jhep.2015.01.013. PubMed DOI PMC

Abenavoli L., Milic N., de Lorenzo A., Luzza F. A pathogenetic link between non-alcoholic fatty liver disease and celiac disease. Endocrine. 2013;43:65–67. doi: 10.1007/s12020-012-9731-y. PubMed DOI

Barone M., Della Valle N., Rosania R., Facciorusso A., Trotta A., Cantatore F.P., Falco S., Pignatiello S., Viggiani M.T., Amoruso A., et al. A comparison of the nutritional status between adult celiac patients on a long-term, strictly gluten-free diet and healthy subjects. Eur. J. Clin. Nutr. 2016;70:23–27. doi: 10.1038/ejcn.2015.114. PubMed DOI

Marra F., Svegliati-Baroni G. Lipotoxicity and the gut–liver axis in NASH pathogenesis. J. Hepatol. 2018;68:280–295. doi: 10.1016/j.jhep.2017.11.014. PubMed DOI

Hendy O.M., Elsabaawy M.M., Aref M.M., Khalaf F.M., Oda A.M.A., El Shazly H.M. Evaluation of circulating zonulin as a potential marker in the pathogenesis of nonalcoholic fatty liver disease. APMIS. 2017;125:607–613. doi: 10.1111/apm.12696. PubMed DOI

Pacifico L., Bonci E., Marandola L., Romaggioli S., Bascetta S., Chiesa C. Increased circulating zonulin in children with biopsy-proven nonalcoholic fatty liver disease. World J. Gastroenterol. 2014;20:17107–17114. doi: 10.3748/wjg.v20.i45.17107. PubMed DOI PMC

Bjorndal B., Alteras E.K., Lindquist C., Svardal A., Skorve J., Berge R.K. Associations between fatty acid oxidation, hepatic mitochondrial function, and plasma acylcarnitine levels in mice. Nutr. Metab. 2018;15:10. doi: 10.1186/s12986-018-0241-7. PubMed DOI PMC

Gaur K., Sakhuja P., Puri A.S., Majumdar K. Gluten-Free hepatomiracle in “celiac hepatitis”: A case highlighting the rare occurrence of nutrition-induced near total reversal of advanced steatohepatitis and cirrhosis. Saudi J. Gastroenterol. 2016;22:461–464. PubMed PMC

Newnham E.D. Coeliac disease in the 21st century: Paradigm shifts in the modern age. J. Gastroenterol. Hepatol. 2017;32(Suppl. 1):82–85. doi: 10.1111/jgh.13704. PubMed DOI

Parzanese I., Qehajaj D., Patrinicola F., Aralica M., Chiriva-Internati M., Stifter S., Elli L., Grizzi F. Celiac disease: From pathophysiology to treatment. World J. Gastrointest. Pathophysiol. 2017;8:27–38. doi: 10.4291/wjgp.v8.i2.27. PubMed DOI PMC

Contribution of Infectious Agents to the Development of Celiac Disease

The Pros and Cons of Using Oat in a Gluten-Free Diet for Celiac Patients